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The Delta variant has become the dominant strain of 
SARS-CoV-2. We summarised the evidence on COVID-
19 vaccine effectiveness (VE) identified in 17 stud-
ies that investigated VE against different endpoints. 
Pooled VE was 63.1% (95% confidence interval (CI): 
40.9–76.9) against asymptomatic infection, 75.7% 
(95% CI: 69.3–80.8) against symptomatic infection 
and 90.9% (95% CI: 84.5–94.7) against hospitalisa-
tion. Compared with the Alpha variant, VE against mild 
outcomes was reduced by 10–20%, but fully main-
tained against severe COVID-19.
The Delta variant (Phylogenetic Assignment of Named 
Global Outbreak (Pango) lineage designation B.1.617.2) 
of severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) was first reported in October 2020 and 
has spread to more than 180 countries globally [1]. 
Concerns were raised about how well the currently 
available vaccines protect against this variant. Since 
January 2021, the Robert Koch Institute (RKI), in col-
laboration with the National Immunisation Technical 
Advisory Groups (NITAGs) network coordinated by the 
European Centre for Disease Prevention and Control 
(ECDC) is performing a living systematic review on the 
efficacy, effectiveness and safety of coronavirus dis-
ease (COVID-19) vaccines authorised in the European 
Union (EU) (PROSPERO registration: CRD42020208935) 
[2]. Here we present results on the effectiveness and 
the duration of protection provided by the EU-licensed 
COVID-19 vaccines in respect to the Delta variant.
Literature search
This living systematic review follows the Preferred 
Reporting Items for Systematic Review and Meta-
Analysis (PRISMA) guideline (Supplement Part S1). 
We considered studies of any design as long as they 
had a comparison group that investigated vaccine 
effectiveness (VE) against SARS-CoV-2 infection of 
any severity after vaccination with a COVID-19 vac-
cine (see Supplement Part S2 for complete population 
intervention comparison outcomes (PICO) question) 
approved by the European Medicines Agency. We did 
not apply any restrictions on publication language and 
status.
We searched the internal COVID-19 literature database 
constructed by the RKI library and hand-searched rel-
evant websites (see [2] and  Supplement Part S3  for 
description of the database and the search strategy). 
Potentially relevant publications were screened at 
title/abstract and full-text level by at least two out 
of three independent investigators (TH, WKS, SR). 
Disagreements on eligibility were resolved through 
discussion. Data were extracted from the included 
studies (see PROSPERO protocol for details) and 
summarised in tables. Only VE estimates of completed 
vaccination schedules were analysed. The risk of bias in 
non-randomized studies – of interventions (ROBINS-I) 
was used to assess risk of bias [3].
We performed meta-analyses, using a random-effects 
model to account for heterogeneity between studies. 
The I2 was used to quantify the extent of heterogeneity. 
Formal testing for publication bias was done for 
datasets with 10 or more estimates by inspection of 
funnel plots, followed by Begg’s test and Egger’s test 
(Supplement Part S4).
Study screening
In total, 7,117 entries were identified and screened until 
25 August 2021, the date of last search. Additionally, 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































hand-searching. After full-text screening, 17 studies 
[4-20] were included (Supplement Part S5: PRISMA 
flowchart).
Types of studies
Included studies reported VE against infections with 
the SARS-CoV-2 Delta variant only, or compared VE 
against the Delta variant with estimates against the 
Alpha (B.1.1.7) variant. Within each of these study 
types, two methodological subtypes were identified: 
(i) studies that calculated VE against Delta and Alpha 
from sequenced samples; or (ii) studies that calculated 
VE from time periods during which Delta and Alpha 
was the dominant strain in the respective study loca-
tion without having sequenced each sample. Two stud-
ies [7,19] also investigated VE at several time points 
after vaccination, thereby addressing waning vaccine-
induced immunity.
Prevention of any infection
Of 17 studies, 10 [4-10,16,17,19] reported the effective-
ness of COVID-19 vaccines in preventing SARS-CoV-2 
infection but did not report whether these were symp-
tomatic or asymptomatic infections;  Table 1  ). Studies 
Figure 1



























10 20 30 40 50 60 70 80 90
RE model subgroup: 68.6% (54.3, 78.3)
I2=97.0%
Nanduri et al. (US) [16] 52.4% (48,56.4) (17.4%)
Authors Country                VE (95% CI)               Weight Authors Country                VE (95% CI)             Weight
Pouwels et al. (UK) [4] 82% (79,85) (17.0%)
Puranik et al. (US) [5] 42% (13,62) (14.4%)
Sheikh et al. (UK) [17] 79% (75,82) (17.0%)
Tang (Qatar) et al.[8]59.6% (50.7,66.9)(16.7%)
Tartof (US) et al. [7] 75% (71,78) (17.2%)
Nanduri et al. (US) [16] 50.6% (45,55.7) (36.9%)
Puranik et al. (US) [5] 76% (58,87) (30.4%)
Tang et al. (Qatar)[8] 86.1 % (78,91.3) (32.6%)
RE model subgroup: 73.8% (44.2,87.7)
I2=91.5%
RE model subgroup: 62.8% (55.8,68.8)
I2=54.19%
Sheikh et al. (UK) [17] 60% (53,66) (41.6%)
Pramod et al. (India)[9]54% (27,71) (11.5%)
Pouwels et al. (UK) [4] 67% (62,71) (46.8%)
Fowlkes et al. (US) [19] 66% (26,84) (23.9%)
RE model subgroup: 53.7% (32.7,68.2)
I2=0%
Elliott et al. (UK) [10] 49% (22,67) (76.0%)
RE model all studies: 66.9% (58.4, 73.6)
I2=95.1%
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RE model subgroup: 59.6% (2.3,83.3)
I2=95.61%
Tang et al. (Qatar) [8] 35.9% (11.1,53.9) (48.7%)
Pouwels et al. (UK) [4] 74% (69,78) (51.2%)
Tang et al. (Qatar) [8] 80.2% (54.2,92.6) (100%)
Pouwels et al. (UK) [4] 57% (51,63) (100%)
RE model all studies : 63.1 % (40.9, 76.9) 
l2=92.97%
Sequencing Dominance Meta−analysis estimate
A. B.
FDA: The United States Food and Drug Administration; RE: Random effects; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; UK: 
United Kingdom; US: United States.
The y-axis illustrates study and reported VE estimates (95 % CI) included in the meta-analysis (inverse variance weight for subgroup meta-
analysis %). The bottom box represents the results of the meta-analysis across all studies for the outcome (RE model all studies: Pooled 
VE% (95% CI) I-square statistic for all studies meta-analysis).
FDA-approved: Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer, Mainz, Germany/New York, United States (US)), Spikevax (mRNA-1273, Moderna, 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































were conducted in four countries. Five were cohort 
studies, three were test-negative case–control stud-
ies and two were based on serial cross-sectional sam-
ples. Six studies investigated more than one vaccine 
(Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer, Mainz, 
Germany/New York, United States (US)) and Spikevax 
(mRNA-1273, Moderna, Cambridge, US) or Comirnaty 
and Vaxzevria (ChAdOx1 nCoV-19, Oxford-AstraZeneca, 
Cambridge, United Kingdom (UK) and COVID-19 Vaccine 
Janssen (Ad26.COV2-S, Janssen-Cilag International NV, 
Beerse, Belgium). One study each evaluated Comirnaty 
and Covishield (Vaxzevria, Serum Institute of India, 
Pune, India) and two studies did not specify the exam-
ined vaccines. The VE estimates in the included studies 
against any type of infection for all age groups, ranged 
between 49% and 82%; in one study with information 
for 18–34-year-olds the range was 90% [4]. Pooled VE 
was 66.9% (95% confidence interval (CI): 58.4–73.6; 
I2 = 95.1%) across all studies (Figure 1 A). 
Prevention of asymptomatic infection
Two studies investigated VE against asymptomatic 
infections (Table 1). These studies were performed in 
the UK and Qatar [4,8]. Both studies investigated two 
vaccines. The VE estimates ranged between 35.9% and 
80.2%. Across studies, pooled VE was 63.1% (95% CI: 
40.9–76.9; I2 = 93%; Figure 1 B).
Prevention of symptomatic infection
Nine studies estimated the effectiveness of COVID-19 
vaccines in preventing symptomatic SARS-CoV-2 infec-
tions (Table 2). Studies were performed in five coun-
tries [4,8-15]. Five studies had a test-negative design, 
two studies applied the screening method and one 
Figure 2



























RE model subgroup: 81.7% (70.2,88.8)
I2=94.17%
Tang et al. (Qatar)      [8] 56.1 % (41.4,67.2) (22.2%)
Pouwels et al. (UK)      [4] 86% (83,88) (23.4%)
Pouwels et al. (UK)      [4] 84% (82,86) (23.7%) 
Nasreen et al. (Canada) [15] 85% (59,94) (12.4%)
Lopez-Bernal et al. (UK) [14] 87.9% (78.2,93.2) (17.9%)
Tang (Qatar)               [8] 85.8% (70.6,93.9) (100%)
RE model subgroup: 69.4% (66.7,72)
l2=0%
Elliott et al. (UK) [10] 59% (23,78) (21.51 %)
Herlihy et al. (US) [11] 78% (71,84) (36.73%)
Keegan et al. (US) [12] 82% (78,85) (41.76%)
RE model subgroup: 76.9% (65.6,84.5)
l2=77.14%
Thiruvengadam et al. (India) [13] 63.1% (51.5,72.1)(9.98%) 
Pramod et al. (India) [9] 64% (38,78) (2.84%)
Pouwels et al. (UK) 71% [4] (66,74) (42.42%)
Pouwels et al. (UK) 70% [4] (66,74) (42.42%)
Lopez-Bernal et al. (UK) [14] 59.8% (28.9,77.3) (2.34%)
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Puranik et al. (US) [5] 75% (24,93.9) (28.2%)
Stowe et al. (UK) [20] 96% (86,99) (26.8%)
Tartof et al. (US) [7] 93% (84,96) (44.9%)
RE model subgroup: 91.4% (78.4,96.6)
l2=54.81 %
Puranik et al.(US) [5] 81% (33,96.3) (100%)
Stowe et al. (UK) [20] 92% (75,97) (100%)
RE model all studies: 90.9% (84.5,94.7)
l2=18.46%
Sequencing Dominance Meta−analysis estimate
A. B.
Vaccine effectives (%) Vaccine effectives (%)
Authors Country                VE (95% CI)               Weight Authors Country                VE (95% CI)               Weight
CI: confidence interval; FDA: The United States Food and Drug Administration; RE: Random effects; SARS-CoV-2: severe acute respiratory 
syndrome coronavirus 2; UK: United Kingdom; US: United States.
The y-axis illustrates study and reported VE estimates (95% CI) included in the meta-analyses (inverse variance weight for subgroup meta-
analysis %). The bottom box represents the results of the meta-analysis across all studies for the outcome (RE model all studies: Pooled 
VE% (95% CI) I-square statistic for all studies meta-analysis).
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study each had a cohort design and used serial cross-
sectional samples. Six studies investigated more than 
one vaccine. The VE against symptomatic infection 
ranged between 56% und 87.9%. The pooled VE esti-
mate was 75.7% (95% CI: 69.3–80.8; I2 = 91.9%; Figure 
2 A).
Prevention of severe disease and hospitalisation
The VE against the compound outcome severe disease 
was assessed in three studies (one cohort, two test-
negative design). They were performed in three coun-
tries (Table 2) [8,13,18]. The VE estimates ranged from 
81.5% to 100% and the pooled VE was 93.8% (95% CI: 
83–98; I2 = 0%;  Supplement Part S6). Hospitalisation 
was reported in four studies: two cohort studies, 
one test-negative design study and one analysis of 
cross-sectional serial samples (Table 2). The studies 
were performed in the US and the UK [5-7,20]. Single 
study VE ranged between 75% and 96%. Pooled VE 
against hospitalisation was 90.9% (95% CI: 84.5–94.7; 
I2 = 18.5%; Figure 2 B). No study reported admission to 
intensive care unit, intubation or death.
Effectiveness against Delta variant compared 
with Alpha variant
In nine studies, VE estimates against infections with the 
Delta variant were compared with those against infec-
tions with the Alpha variant in the same study for at 
least one outcome (Tables 1 and 2). Overall, VE against 
Delta was 10–20% lower than VE against Alpha for less 
severe outcomes. For hospitalisation, VE against Delta 
did not differ from VE against Alpha.
Waning protection
Two cohort studies from the US investigated VE against 
infections (symptomatic or asymptomatic) for more than 
one time point after vaccination. One study reported a 
decrease of protection offered by the Comirnaty vac-
cine from 93% (95% CI: 85–97) at baseline to 53% (95% 
CI: 39‒65) after at least 4 months [7]. The other study 
investigated protection conferred by any FDA-licensed 
vaccines in frontline workers (healthcare workers and 
others) and reported a non-significant change from 
85% (95% CI: 68–93) to 73% (95% CI: 49–86) after at 
least 5 months following full vaccination [19].
Risk of bias
14 studies [4,5,7-10,13-20] had a moderate risk of bias 
and three studies [6,11,12] had a critical risk of bias. 
Major limitations were incomplete or absent adjust-
ment for confounders (see  Supplement Part S7  for 
details). No evidence of publication bias was detected.
Discussion
These second interim results of our living systematic 
review show that COVID-19 vaccines approved in the 
EU have a moderate to high effectiveness against mild 
to moderate forms of SARS-CoV-2 infections caused 
by the Delta variant, while VE against severe disease 
and hospitalisation was high to very high. Statistical 
heterogeneity was low in meta-analysis of the severe 
outcomes, further supporting a well-maintained effec-
tiveness against these endpoints under Delta variant 
dominance.
In one study where VE was investigated in more than 
one age group, higher estimates in younger groups 
were seen. Of note, no VE estimate against Delta had 
been reported until data cut (25 August) for the Janssen 
vaccine.
As already discussed in the first interim analysis [2] 
and given the highly dynamic publishing landscape 
in this field, we cannot exclude the possibility that 
additional published studies were not captured by our 
search strategy. Further limitations stem from the fact 
that genomic sequencing was used to determine VE 
against Delta in only a minority of studies, while in the 
majority of studies VE was estimated during time peri-
ods of dominant Delta circulation without sequencing. 
Moreover, based on the current evidence, it is chal-
lenging to segregate two factors contributing to the dif-
ference between the VE estimates against Alpha and 
Delta variants: waning immunity and actual VE against 
Delta. Furthermore, a number of studies did not report 
separate estimates per vaccine.
Conclusion
Current evidence shows that COVID-19 vaccines 
licensed in the EU are moderately to highly effective 
in preventing SARS-CoV-2 infections with the Delta 
variant, while effectiveness against severe courses of 
COVID-19 remains high.
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